ANTHRASIL
Total Payments
$35,379
Transactions
2
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $35,379 | 2 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $35,379 | 2 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| AX003A | Emergent BioSolutions Inc. | $35,379 | 0 |
Top Doctors Receiving Payments for ANTHRASIL
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Omaha, NE | $35,379 | 2 |
Ad
Manufacturing Companies
- Emergent BioSolutions Inc. $35,379
Product Information
- Type Drug
- Total Payments $35,379
- Total Doctors 0
- Transactions 2
About ANTHRASIL
ANTHRASIL is a drug associated with $35,379 in payments to 0 healthcare providers, recorded across 2 transactions in the CMS Open Payments database. The primary manufacturer is Emergent BioSolutions Inc..
Payment data is available from 2019 to 2019. In 2019, $35,379 was paid across 2 transactions to 0 doctors.
The most common payment nature for ANTHRASIL is "Unspecified" ($35,379, 100.0% of total).
ANTHRASIL is associated with 1 research study, including "AX003A" ($35,379).